Evidence map›Paper›PMID 34884585›Full record

ArticleInternational journal of molecular sciences2021

Proteomic Changes of Activated Hepatic Stellate Cells.

Maximilian Schinagl, Tamara Tomin, Juergen Gindlhuber, Sophie Honeder, Raphael Pfleger, Matthias Schittmayer, Michael Trauner, Ruth Birner-Gruenberger

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Gut-Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3/c-Myc Signaling Axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Mass Spectrometric Proteomics 2022.International journal of molecular sciences · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Maximilian SchinaglInstitute of Chemical Technologies and Analytics, Technische Universität Wien, 1060 Vienna, Austria.ORCID 0000-0003-1009-7208
Tamara TominInstitute of Chemical Technologies and Analytics, Technische Universität Wien, 1060 Vienna, Austria.ORCID 0000-0002-7071-2316
Juergen GindlhuberDepartment of Pathology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-6155-5208
Sophie HonederDepartment of Pathology, Medical University of Graz, 8010 Graz, Austria.ORCID 0000-0002-7201-6293
Raphael PflegerInstitute of Chemical Technologies and Analytics, Technische Universität Wien, 1060 Vienna, Austria.
Matthias SchittmayerInstitute of Chemical Technologies and Analytics, Technische Universität Wien, 1060 Vienna, Austria.ORCID 0000-0003-3249-655X
Michael TraunerHans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-1275-6425
Ruth Birner-GruenbergerInstitute of Chemical Technologies and Analytics, Technische Universität Wien, 1060 Vienna, Austria.ORCID 0000-0003-3950-0312
TU Wien · ATMedical University of Graz · ATMedical University of Vienna · AT

Funding

Austrian Science Fund FWF W 1226FWF Austrian Science Fund F73FWF Austrian Science Fund W1226
6 · The paper itself

Abstract

Hepatic stellate cells (HSC) are the major cellular drivers of liver fibrosis. Upon liver inflammation caused by a broad range of insults including non-alcoholic fatty liver, HSC transform from a quiescent into a proliferating, fibrotic phenotype. Although much is known about the pathophysiology of this process, exact cellular processes which occur in HSC and enable this transformation remain yet to be elucidated. In order to investigate this HSC transformation, we employed a simple, yet reliable model of HSC activation via an increase in growth medium serum concentration (serum activation). For that purpose, immortalized human LX-2 HSC were exposed to either 1% or 10% fetal bovine serum (FBS). Resulting quiescent (1% FBS) and activated (10% FBS) LX-2 cells were then subjected to in-depth mass spectrometry-based proteomics analysis as well as comprehensive phenotyping. Protein network analysis of activated LX-2 cells revealed an increase in the production of ribosomal proteins and proteins related to cell cycle control and migration, resulting in higher proliferation and faster migration phenotypes. Interestingly, we also observed a decrease in the expression of cholesterol and fatty acid biosynthesis proteins in accordance with a concomitant loss of cytosolic lipid droplets during activation. Overall, this work provides an update on HSC activation characteristics using contemporary proteomic and bioinformatic analyses and presents an accessible model for HSC activation. Data are available via ProteomeXchange with identifier PXD029121.

Indexed as

AnimalsCattleCell MovementCell ProliferationHepatic Stellate CellsHumansProteomeSerum Albumin, BovineProteomeSerum Albumin, Bovineactivationfibrosishepatic stellate cellsproteomics

Identifiers

PMID34884585
PMCPMC8657869
OpenAlexW3217476520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.